Subject(s)
Antibodies, Monoclonal/administration & dosage , Still's Disease, Adult-Onset/drug therapy , Adult , Dose-Response Relationship, Drug , Drug Administration Schedule , Follow-Up Studies , Humans , Infliximab , Infusions, Intravenous , Male , Risk Assessment , Severity of Illness Index , Still's Disease, Adult-Onset/diagnosis , Treatment OutcomeABSTRACT
OBJECTIVE: To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors. METHOD: A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery. RESULTS: The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P = 0.05). CONCLUSION: Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol.
